AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05942859 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Artificial Intelligence and Machine Learning technology
Description: Artificial Intelligence describes computer software designed to mimic human cognitive function. Machine learning is a type of artificial intelligence in which the model created is exposed to data, identifies patterns, and recognises relationships between features seen in the data and the 'ground truth'. This technology will be applied to participants ECGs.
Study NCT05653726 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telemonitoring follow-up using medical devices and telematic consultations
Description: Home telemonitoring of blood pressure, heart rate and peripheral oxygen saturation on a daily basis during 12 months
Study NCT04662580 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARX517
Description: ARX517 is an ADC consisting of a humanized anti-PSMA monoclonal antibody (mAb) (IgG1κ) covalently conjugated to two (2) proprietary microtubule-disrupting toxins referred to as AS269.
Study NCT04662580 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apalutamide
Description: Oral tablet and will be given once daily by mouth.
Study NCT04662580 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone acetate
Description: Oral tablet and will be given once daily by mouth.
Study NCT04662580 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Oral tablet and will be given once daily in metastatic castration-sensitive prostate cancer( mCSPC) and twice daily in metastatic castration-resistant prostate cancer (mCRPC) cohort by mouth.
Study NCT06518525 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pilates-based tele-exercises
Description: pilates-based tele-exercises
Study NCT04925752 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Lenacapavir (LEN)
Description: Tablets administered orally without regard to food
Study NCT04925752 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: F/TDF
Description: Tablets administered orally
Study NCT04925752 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sub-cutaneous (SC) Lenacapavir (LEN)
Description: Administered via SC injections
Study NCT04925752 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo SC LEN
Description: Administered via SC injections
Study NCT04925752 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PTM F/TDF
Description: Tablets administered orally
Study NCT04925752 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PTM Oral LEN
Description: Tablets administered orally
Study NCT04925752 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: F/TAF (for US participants only)
Description: F/TAF tablets administered orally once daily
Study NCT05091671 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Free From Pain Exercise Programme Variation 1
Description: Includes the initial 45-minute consultation + the exercise booklet + the 12 reasons to exercise leaflets + the 12 metaphor leaflets.
Study NCT05037994 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Ultrasound Guided Continuous Suprascapular Nerve Block With methyl prednisolone and marcaine
Description: The high frequency linear ultrasound transducer (Sonosite 6-13 MHz) in a transverse orientation will be placed over the scapular Spine.~Moving the transducer cephalad the suprascapular fossa will be identified. 18 gauge touhy needle will be inserted in plane after subcutaneous local anesthesia infiltration with 1 ml lidocaine 2% Real-time imaging will be used to direct injection of 2 ml lidocaine 2% to test perineural spread of injectate after confirmation of the position of tip of needle injection of 40mg methyl prednisolone diluted in 5 ml bupivacaine 0.5% will be done through the needle to anesthetize the nerve and create space for catheter insertion. After catheter insertion another 2 ml lidocaine 2% will be injected through the catheter to confirm position perineural in the scapular notch. Lastly Catheter will be fixed via skin tunnel and secured with skin sutures and adhesive tap.
Study NCT05037994 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound Guided Continuous Suprascapular Nerve Block With methyl prednisolone and marcaine
Description: The high frequency linear ultrasound transducer (Sonosite 6-13 MHz) in a transverse orientation will be placed over the scapular Spine.~Moving the transducer cephalad the suprascapular fossa will be identified. 18 gauge touhy needle will be inserted in plane after subcutaneous local anesthesia infiltration with 1 ml lidocaine 2% Real-time imaging will be used to direct injection of 2 ml lidocaine 2% to test perineural spread of injectate after confirmation of the position of tip of needle injection of 40mg methyl prednisolone diluted in 5 ml bupivacaine 0.5% will be done through the needle to anesthetize the nerve and create space for catheter insertion. After catheter insertion another 2 ml lidocaine 2% will be injected through the catheter to confirm position perineural in the scapular notch. Lastly Catheter will be fixed via skin tunnel and secured with skin sutures and adhesive tap.
Study NCT05091671 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Free From Pain Exercise Programme Variation 2
Description: Includes the initial 45-minute consultation + the exercise booklet + the 12 reasons to exercise leaflets + the 12 metaphor leaflets, and the 12 Zoom online sessions.
Study NCT01600807 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine, Erlotinib, OSI-906
Description: Gemcitabine 1000 mg/m2 d1,8,15; Erlotinib 100 mg QD, OSI-906 dose to be determined BID
Study NCT01600807 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine, Erlotinib
Description: Gemcitabine 1000 mg/m2 d1,8,15; Erlotinib 100 mg QD
Study NCT05252065 — intervention group
Intervention type: OTHER
Intervention: Cardiac biomarkers, Echocardiography,Cardiac magnetic resonance imaging
Description: Troponin I, troponin T, hypersensitive troponin, brain natriuretic peptide and NT-proBNP are detected for cardiac biomarkers;echocardiography and cardiac magnetic resonance imaging are used to measure the functions of heart and vessels.
Study NCT06491979 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin A treatment
Description: Vitamin A, 32 microgram per kilograms (of body weight) per day, for three weeks
Study NCT06491979 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Monounsaturated fatty acid mixture
Description: Monounsaturated fatty acid mixture (mainly Omega-7, Omega-9), 47 milligrams per kilogram (of body weight) per day, for three weeks
Study NCT06491979 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Polyunsaturated fatty acid mixture
Description: Polyunsaturated fatty acid mixture (mainly Omega-3, Omega-6), 6 milligrams per kilogram (of body weight) per day, for three weeks
Study NCT06569745 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Verbal Explanation
Description: In the verbal explanation group, a researcher wearing white coat provided oral and dental health education for 3 minutes using a jaw model
Study NCT06569745 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Animation Video Display
Description: In the animation group, oral and dental health education was presented to the children in the form of a cartoon lasting 1 minute and 17seconds. The animation video was created by the researcher using the test version of www.vyond.com. The animation featured a character voiced by one of the researchers, informative texts, and background music. The character conveyed information about oral and dental health education, using both voice and text content.
Study NCT06569745 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Peer-Led Reels Video Display
Description: In the peer-led reels group, oral and dental health information was presented for 1 minute using a video created on the Instagram platform. The video showed oral hygiene information being provided to a child of a similar age to the target audience with the child then demonstrating the behaviour with music in the background. The video included some text, but did not feature the child's voice or information.
Study NCT06494072 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ampicillin for Injection
Description: Ampicillin is an intravenous antibiotic commonly used in the initial treatment of children hospitalized with community-acquired pneumonia.
Study NCT06494072 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ampicillin for Injection
Description: Ampicillin is an intravenous antibiotic commonly used in the initial treatment of children hospitalized with community-acquired pneumonia.
Study NCT06494072 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ceftriaxone for Injection
Description: Ceftriaxone is an intravenous antibiotic commonly used in the initial treatment of children hospitalized with community-acquired pneumonia.
Study NCT06494072 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ceftriaxone for Injection
Description: Ceftriaxone is an intravenous antibiotic commonly used in the initial treatment of children hospitalized with community-acquired pneumonia.
Study NCT06494072 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin
Description: Amoxicillin is an oral antibiotic commonly used in the treatment of children hospitalized with community-acquired pneumonia to complete the antibiotic course after discharge.
Study NCT05345158 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Robotic Retroperitoneal Lymph Node Dissection (RPLND)
Description: Robotic RPLND performed using the DaVinci robotic surgical system.
Study NCT04704843 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guselkumab
Description: Guselkumab will be administered as IV infusion (induction dose) and SC injection.
Study NCT04704843 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo to guselkumab will be administered as IV infusion (induction dose) and SC injection.
Study NCT04208464 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baricitinib
Description: 4mg daily for 24 weeks from baseline
Study NCT04208464 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baricitinib
Description: 4mg daily for 24 weeks starting after a 12-week treatment delay from baseline
Study NCT06494072 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxicillin
Description: Amoxicillin is an oral antibiotic commonly used in the treatment of children hospitalized with community-acquired pneumonia to complete the antibiotic course after discharge.
Study NCT06494072 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ampicillin / Sulbactam Injection
Description: Ampicillin/Sulbactam is an intravenous antibiotic commonly used in the initial treatment of children hospitalized with community-acquired pneumonia.
Study NCT06494072 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ampicillin / Sulbactam Injection
Description: Ampicillin/Sulbactam is an intravenous antibiotic commonly used in the initial treatment of children hospitalized with community-acquired pneumonia.
Study NCT06494072 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin-clavulanate
Description: Amoxicillin-clavulanate is an oral antibiotic commonly used in the treatment of children hospitalized with community-acquired pneumonia to complete the antibiotic course after discharge.
Study NCT06494072 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxicillin-clavulanate
Description: Amoxicillin-clavulanate is an oral antibiotic commonly used in the treatment of children hospitalized with community-acquired pneumonia to complete the antibiotic course after discharge.
Study NCT06494072 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clindamycin
Description: Clindamycin is an antibiotic that can be given intravenously or orally that is sometimes used in the treatment of children hospitalized or discharged with community-acquired pneumonia.
Study NCT06494072 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clindamycin
Description: Clindamycin is an antibiotic that can be given intravenously or orally that is sometimes used in the treatment of children hospitalized or discharged with community-acquired pneumonia.
Study NCT06494072 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cefprozil
Description: Cefprozil is an oral antibiotic sometimes used in the treatment of children hospitalized with community-acquired pneumonia to complete the antibiotic course after discharge.
Study NCT06494072 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cefprozil
Description: Cefprozil is an oral antibiotic sometimes used in the treatment of children hospitalized with community-acquired pneumonia to complete the antibiotic course after discharge.
Study NCT06494072 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levofloxacin
Description: Levofloxacin is an antibiotic that can be given intravenously or orally that is sometimes used in the treatment of children hospitalized or discharged with community-acquired pneumonia.
Study NCT06494072 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levofloxacin
Description: Levofloxacin is an antibiotic that can be given intravenously or orally that is sometimes used in the treatment of children hospitalized or discharged with community-acquired pneumonia.
Study NCT06302062 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tumor Associated Lymph node T cell
Description: At least one lymph sample is resected from each participant, then it is separated and cultured ex vivo to expand the population of Tumor Associated Lymph node T cells (FIT003 TAL-T). After lymphodepletion, patients are infused with FIT003 TAL-T.
Study NCT06300684 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy for Insomnia (CBT-i)
Description: This intervention involves structured sessions aimed at addressing maladaptive sleep behaviors and promoting healthy sleep habits. Participants in this group will engage in cognitive restructuring, relaxation techniques, and sleep hygiene education to improve sleep quality and duration. The goal of CBTi is to modify behaviors and thoughts that contribute to insomnia, leading to more restful and consolidated sleep patterns.
Study NCT05725434 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CT-P47 AI (tocilizumab)
Description: CT-P47 (162 mg/0.9 mL) by subcutaneous (SC) injection via autoinjector (AI) at Week 0 and Week 2
Study NCT05725434 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CT-P47 PFS (tocilizumab)
Description: CT-P47 (162 mg/0.9 mL) by SC injection via pre-filled syringe from Week 4 every other week or weekly (based on the clinical response by investigator's discretion) up to Week 10
Study NCT06214325 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Music Therapy
Description: Board-certified music therapists (i.e., MT-BC credential) will provide two music therapy sessions, a minimum of 24 hours apart, that include education and disease-specific content (e.g., harmonica exercises for respiratory health \[COPD\] or music-based breathing exercises \[HF\]) prior to patients' discharge and two virtual music therapy sessions that address music-assisted relaxation and imagery, additional techniques for managing psychosocial stressors, and gratitude exercises post-discharge.
Study NCT06468943 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polatuzumab Vedotin
Description: 1.8mg/kg/21d（d0） Intravenous infusion
Study NCT06468943 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zanubrutinib
Description: 160mg bid PO（d0-d20）
Study NCT06468943 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 375mg/㎡/21d（d0） Intravenous infusion
Study NCT06468943 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 750mg/㎡/21d（d1） Intravenous infusion
Study NCT06468943 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: 50mg/㎡/21d（d1） Intravenous infusion
Study NCT06468943 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: 100mg PO （d1-d5）/21d
Study NCT05043831 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DSLT
Description: Direct-SLT is applied via the limbus to the trabecular meshwork
Study NCT05043831 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: DSLT
Description: Direct-SLT is applied via the limbus to the trabecular meshwork
Study NCT05533372 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IA-14069
Description: IA-14069 for oral administration.
Study NCT06410404 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: transversus thoracis plane block
Description: with the patient lying in the supine position. After skin disinfection, a high frequency linear ultrasound probe will be applied parallel to and between the 4th and 5th ribs connecting at the sternum. Then, different drugs according to the different groups will be injected between the transversus thoracic muscle and the internal intercosatal muscle.
Study NCT06410404 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: the dexmeditomedine group shall undergo bilateral transversus thoracis plane block with 15 ml of 25% levobupivacaine, and 0.05 ug/kg dexmeditomedine on each side of the sternum
Study NCT06410404 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levobupivacaine
Description: A local anesthetic that will be instilled in the transversus thoracic plane in a dose of 15 ml of a 25% concentration on both sides of the sternum in both groups
Study NCT05533372 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo for oral administration.
Study NCT05533372 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Methotrexate for oral administration.
Study NCT05917145 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WSD0628
Description: A non-toxic compound and inhibits the DNA damage response associated with radiation therapy. • WSD-0628 radio sensitizes Glioblastoma cells.
Study NCT06302062 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: A one-day intravenous injection of cyclophosphamide was administered two days prior to the initial cell transfusion.
Study NCT06302062 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IL-2
Description: The IL-2 treatment will be continued for 5 days.
Study NCT06302062 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Serplulimab Injection
Description: In group B, Serplulimab Injection was injected before and after cell transfusion. If two cell transfusions were performed,Serplulimab Injection were given again .
Study NCT05407220 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HCP1904-1
Description: take it once per period
Study NCT05407220 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HCP1904-3
Description: take it once per period
Study NCT04486638 — intervention group
Intervention type: BIOLOGICAL
Intervention: Dengue Tetravalent Vaccine, Live
Description: Pharmaceutical form: Powder and solvent for suspension for injection Route of administration: Subcutaneous
Study NCT06174259 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: intermittent fasting
Description: 16/8 intermittent fasting (limiting foods and calorie-containing beverages to a set window of 8 hours per day)
Study NCT05588271 — intervention group
Intervention type: OTHER
Intervention: Exposures
Description: This study is an observational study.Exposure factors is patients with pressure injury.
Study NCT04684290 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Alcohol Septal Ablation
Description: Participants will be treated with alcohol septal ablation.
Study NCT04684290 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgical Septal Myectomy
Description: Participants will be treated with surgical septal myectomy.
Study NCT05068310 — intervention group
Intervention type: DEVICE
Intervention: Cellular resolution full-field optical coherence tomography
Description: Device: ApolloVue® S100 Image System
Study NCT05068310 — intervention group
Intervention type: DEVICE
Intervention: Confocal microscopy
Description: Device: Vivascope® will be used for skin imaging for a subset of skin lesions.
Study NCT06491979 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fatty acid mixture
Description: Fatty acid mixture (mainly saturated fatty acid, Omega-6, Omega-7, Omega-9), 83 milligrams per kilogram (of body weight) per day, for three weeks
Study NCT06176885 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab
Description: Combination therapy with Camrelizumab monoclonal antibody will be administered after the initial two cycles of induction therapy.
Study NCT05068310 — intervention group
Intervention type: DEVICE
Intervention: Optical coherence tomography imaging
Description: Device: Vivosight® will be used for skin imaging for a subset of skin lesions.
Study NCT05068310 — intervention group
Intervention type: DEVICE
Intervention: Dermoscopy imaging
Description: Device: Dermoscopy imaging will be conducted using but not limited to dermoscope DermLite FotoX®
Study NCT05370209 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Otinova® Ear Spray
Description: Ear spray